SCHEMBL16285694

SCHEMBL16285694

CN1CCN(c2ccc(Nc3ccc4ccc(=O)n(Cc5c(F)cccc5Cl)c4c3)cc2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WEE1 P30291 8/20 0.46
MAPT P10636 2/20 0.46
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
MAPK1 P28482 1/20 0.46
MPI P34949 1/20 0.46
KMT2A Q03164 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CDK4 P11802 2/20 0.44
CCND1 P24385 2/20 0.44
CCND2 P30279 2/20 0.44
CCND3 P30281 2/20 0.44
TSHR P16473 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
FGFR1 P11362 2/20 0.43
SRC P12931 2/20 0.43
CYP3A4 P08684 1/20 0.42
NTRK1 P04629 1/20 0.42
KDM1A O60341 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16285701 0.93 CDK4 (0.47) WEE1CDK4CCND1CCND2CCND3
SCHEMBL16285708 0.93 CDK4 (0.47) WEE1CDK4CCND1CCND2CCND3
SCHEMBL16285707 0.91 CDK4 (0.44) WEE1CDK4CCND1CCND2CCND3
SCHEMBL16285705 0.90 CDK4 (0.44) WEE1CDK4CCND1CCND2CCND3
SCHEMBL16285710 0.90 WEE1 (0.46) WEE1CDK4CCND1CCND2CCND3
SCHEMBL16285711 0.89 CDK4 (0.44) WEE1CDK4CCND1CCND2CCND3
SCHEMBL16286128 0.88 CDK4 (0.46) WEE1CDK4CCND1CCND2CCND3
SCHEMBL16285703 0.88 CDK4 (0.42) WEE1CDK4CCND1CCND2CCND3
SCHEMBL16285704 0.88 CDK4 (0.42) MAPTMAPK1KMT2ACDK4CCND1
SCHEMBL16285688 0.87 FYN (0.46) WEE1CDK4CCND1CCND2CCND3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140364430-A1 METHODS FOR TREATING SCHIZOPHRENIA AFRAXIS HOLDINGS INC (US) 2014-12-11 US disclosed
US-20140364430-A1 METHODS FOR TREATING SCHIZOPHRENIA AFRAXIS HOLDINGS INC (US) 2014-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140364430-A1 METHODS FOR TREATING SCHIZOPHRENIA GRIN2A, GRIN2C, GRIN3A WEE1 4223/4885MAPT 679/4885KDM4E 3382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.